- Login
- Register & Subscribe
- Langue: EN FR DE
Company News
Roche signals cutbacks
Friday 3 September 2010
The Roche Group has launched a review of its staffing levels and other expenses in light of pressure on revenue from healthcare reform in the US and Europe and set-backs in its late-stage drug pipeline. Details will be announced before the end of 2010.
Location
Switzerland
See map: Google Maps
FDA rejects motavizumab again
Tuesday 31 August 2010
The US Food and Drug Administration has issued its second ‘complete response letter’ to the AstraZeneca unit, MedImmune, rejecting its application to market motavizumab, a new monoclonal antibody for respiratory syncytial virus disease.
Location
United Kingdom
See map: Google Maps
Roche invests in peptide technology
Tuesday 31 August 2010
The Roche Group has announced plans to invest $25 million upfront for access to new peptide technology that locks peptides into their biologically active shape, mimicking the structures found in nature.
Location
Switzerland
See map: Google Maps
Genzyme rejects Sanofi offer
Monday 30 August 2010
Genzyme Corp has rejected an unsolicited cash takeover bid from Sanofi-Aventis which values the company at $69 per share or $18.5 billion. The rejection was communicated in a letter to the Sanofi CEO Christopher Viehbacher.
Location
United States
See map: Google Maps
FDA approves Novartis blood pressure drug
Friday 27 August 2010
The US Food and Drug Administration has approved a new treatment for high blood pressure from Novartis which combines the renin inhibitor, aliskiren, with the calcium channel blocker, amlodipine, in a single pill.
Location
United States
See map: Google Maps
New drug development company set up in the Benelux
Thursday 26 August 2010
A new company has been set up in the Benelux to discover and develop small molecule drugs for treating bone and joint diseases. It combines assets from TiGenix NV of Belgium and Therosteon BV of the Netherlands.
Location
Belgium
CRT and Bayer to investigate new approach to gynaecological diseases
Wednesday 25 August 2010
Cancer Research Technology of the UK has signed an agreement with Bayer Schering Pharma AG to evaluate new leptin antagonist peptides as potential treatments for gynaecological diseases, including cancer.
Location
United Kingdom
See map: Google Maps
Roche to pay $100 million for US diagnostics company
Monday 23 August 2010
The Roche Group has announced plans to acquire privately-owned BioImagene Inc of Sunnyvale, California for $100 million in order to bolster its position as a provider of personalised medicines. BioImagene develops digital pathology services.
Location
Switzerland
See map: Google Maps
FDA grants priority review to belimumab
Friday 20 August 2010
The US Food and Drug Administration has granted priority review status to belimumab, a potential treatment for systemic lupus erythematosus, according to the drug’s co-developers, GlaxoSmithKline Plc and Human Genome Sciences Inc.
Location
United States
See map: Google Maps
Adult stem cells repair heart tissue in animal model
Friday 20 August 2010
Preclinical research showing that reprogrammed adult stem cells can repair damaged heart tissue in mice has been published in the Journal of the American College of Cardiology. The technology is also being tested in a human trial in Europe.
Location
Belgium
Select a News Category
Recent Appointments
Tim Edwards elected chairman of BIA
Tuesday September 7 2010
Index Ventures appoints antibody expert as partner
Friday September 3 2010
Colin Stewart appointed CEO at Amarin
Friday August 20 2010
Karl Keegan nominated as CFO of Pharming
Friday August 20 2010
Axel Müller becomes CEO at SkyePharma
Thursday August 19 2010